Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair issued their Q1 2019 earnings estimates for shares of Hologic in a note issued to investors on Saturday. William Blair analyst B. Weinstein forecasts that the medical equipment provider will post earnings of $0.60 per share for the quarter. William Blair also issued estimates for Hologic’s Q2 2019 earnings at $0.60 EPS, Q3 2019 earnings at $0.65 EPS and Q4 2019 earnings at $0.65 EPS.

How to Become a New Pot Stock Millionaire

HOLX has been the topic of several other research reports. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 target price on the stock in a research note on Wednesday, December 20th. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Friday, January 19th. Stifel Nicolaus cut shares of Hologic from a “buy” rating to a “hold” rating and lowered their target price for the company from $45.00 to $42.00 in a research note on Friday, February 9th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $50.00 target price (up previously from $48.00) on shares of Hologic in a research note on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Hologic has a consensus rating of “Buy” and a consensus price target of $48.00.

Hologic (NASDAQ:HOLX) traded up $0.22 on Tuesday, reaching $38.41. 1,529,211 shares of the company’s stock traded hands, compared to its average volume of 2,622,285. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. The company has a market cap of $10,455.57, a PE ratio of 10.07, a P/E/G ratio of 1.71 and a beta of 0.84. Hologic has a 1-year low of $35.33 and a 1-year high of $46.80.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million for the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 EPS.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parnassus Investments CA raised its stake in Hologic by 88.6% during the 4th quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after acquiring an additional 6,689,454 shares during the period. Victory Capital Management Inc. raised its stake in Hologic by 5.8% during the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock worth $265,008,000 after acquiring an additional 342,239 shares during the period. Two Sigma Advisers LP raised its stake in Hologic by 28.1% during the 4th quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock worth $120,910,000 after acquiring an additional 620,761 shares during the period. Dimensional Fund Advisors LP raised its stake in Hologic by 5.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock worth $72,243,000 after acquiring an additional 105,360 shares during the period. Finally, Guggenheim Capital LLC raised its stake in Hologic by 46.0% during the 4th quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock worth $71,053,000 after acquiring an additional 523,654 shares during the period. Institutional investors own 97.56% of the company’s stock.

In other news, Director Namal Nawana bought 6,600 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were bought at an average price of $37.88 per share, for a total transaction of $250,008.00. Following the purchase, the director now owns 6,954 shares in the company, valued at $263,417.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Charles J. Dockendorff bought 13,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were purchased at an average price of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. 0.88% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/hologic-inc-forecasted-to-post-q1-2019-earnings-of-0-60-per-share-holx/1957062.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.